WINTON GROUP Ltd Sells 21,054 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

WINTON GROUP Ltd reduced its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 72.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 7,891 shares of the biotechnology company’s stock after selling 21,054 shares during the quarter. WINTON GROUP Ltd’s holdings in Arrowhead Pharmaceuticals were worth $524,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vise Technologies Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $268,000. State of Wyoming boosted its position in shares of Arrowhead Pharmaceuticals by 6.2% during the 4th quarter. State of Wyoming now owns 10,110 shares of the biotechnology company’s stock valued at $671,000 after acquiring an additional 591 shares during the last quarter. TD Asset Management Inc bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $3,705,000. Elgethun Capital Management bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $266,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Arrowhead Pharmaceuticals by 9.0% during the 4th quarter. Bank of New York Mellon Corp now owns 887,848 shares of the biotechnology company’s stock valued at $58,944,000 after acquiring an additional 73,300 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Royal Bank Of Canada raised their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Sanford C. Bernstein raised their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $87.80.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. This trade represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the sale, the chief financial officer owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 26,065 shares of company stock worth $1,912,662. 3.60% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Stock Down 3.5%

Shares of ARWR opened at $70.73 on Thursday. The company has a market cap of $9.96 billion, a PE ratio of -32.90 and a beta of 1.28. The business has a fifty day moving average of $71.99 and a 200 day moving average of $66.41. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $14.30 and a 52-week high of $82.26. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. The company had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s revenue was down 86.4% on a year-over-year basis. During the same period last year, the company earned $2.75 earnings per share. On average, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.